Vascular Biogenics Ltd. (VBLT)

Trade VBLT now with
4/9/2021 9:16:26 AM Vascular Biogenics Reports Pricing Of Public Offering Of 5.15 Mln Ordinary Shares At $1.90/Shr
1/15/2021 7:26:28 AM VBL Therapeutics Enters Into Ordinary Share Purchase Agreement Of Up To $20 Mln With Aspire Capital Fund
12/29/2020 7:08:13 AM VBL Therapeutics Announces Expansion Of Ongoing OVAL Phase 3 Study On Ofranergene Obadenovec
10/13/2020 7:18:58 AM VBL Therapeutics Appoints Marc Kozin As Vice Chairman Of Board
10/12/2020 7:14:11 AM VBL Therapeutics Says Newly Granted European Patent Protects Anti-MOSPD2 Antibodies Until At Least July 2036
6/1/2020 7:18:59 AM VBL Therapeutics Presents Positive Interim Data From OVAL Phase 3 Pivotal Study In Ovarian Cancer At ASCO20
8/13/2019 7:29:13 AM VBL Therapeutics Q2 Net Loss $4.7 Mln Or $0.13 Per Share
5/15/2019 7:20:17 AM VBL Therapeutics Q1 Net Loss $4.2 Mln Or $0.12/Shr Vs Loss Of $7.2 Mln Or $0.24/Shr Last Year
3/19/2019 7:05:39 AM VBL Presents New Data On Potential Of VB-111 To Stimulate Immune System Against Ovarian Tumors
11/20/2018 7:11:00 AM VBL Therapeutics Q3 Loss $5.4 Mln Or $0.15/Shr Vs Loss Of $6.5 Mln Or $0.24/Shr Last Year
6/27/2018 4:03:15 PM VBL Therapeutics Closes $15.5 Mln Registered Direct Offering
3/15/2018 7:17:04 AM VBL Therapeutics FY Comprehensive Loss $10.2 Mln Or $0.37/Shr Vs Loss Of $16.0 Mln Or $0.64/Shr Last Year
3/8/2018 6:05:19 AM VBL Therapeutics Announces Top-Line Results From Pivotal Phase 3 GLOBE Study In Patients With Recurrent Glioblastoma
1/3/2018 7:06:46 AM VBL Therapeutics Appoints David Hastings And Susan Kelley To Its Board